Meeting
2015 ASCO Annual Meeting
Phase 2 studies of multiple peptides cocktail vaccine for treatment-resistant cervical and ovarian cancer.
Authors
Satoshi Takeuchi
Iwate Medical University, Morioka Iwate, Japan
Satoshi Takeuchi , Tadahiro Shoji , Masahiro Kagabu , Tatsuya Honda , Atsumi Kojima , Yukari Nitta , Toru Sugiyama , Yusuke Nakamura
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
UMIN000003860,3862,3902,3903
Citation
J Clin Oncol 33, 2015 (suppl; abstr 5567)
DOI
10.1200/jco.2015.33.15_suppl.5567
Abstract #
5567
Poster Bd #
125
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC): Preliminary results of the SPENCER study.
First Author: Eric Baudin
Poster
2021 ASCO Annual Meeting
Efficacy finding cohort of a cancer peptide vaccine, TAS0313, in treating recurrent glioblastoma.
First Author: Yoshiki Arakawa
Poster
2015 ASCO Annual Meeting
A phase II study of novel three peptides combination with gemcitabine as a first-line therapy for advanced pancreatic cancer (VENUS-PC study).
First Author: Hiroaki Tanaka
Poster
2014 ASCO Annual Meeting
Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients with induced immune responses and a prolonged OS.
First Author: Yoshihiro Yoshitake